Telmisartan for Treatment of COVID-19 Patients

Administrative information

1. Title: Telmisartan for Treatment of COVID-19 Patients: An Open Label Randomized Trial.
2. Trial registration:
   1. ClinicalTrials.gov: NCT04355936

|  |  |
| --- | --- |
| Data category | Information |
| Primary registry and trial identifying number | ClinicalTrials.gov NCT04355936 |
| Date of registration in primary registry | 21 April, 2020 |
| Secondary identifying numbers | N/A |
| Source(s) of monetary or material support | Dr. Carlos R. Rojo, MD. |
| Primary sponsor | School of Medicine, University of Buenos Aires. |
| Secondary sponsor(s) | Laboratorio Elea Phoenix, SA. |
| Contact for public queries | *Rodolfo P. Rothlin, MD: safc@ama-med.org.ar* |
| Contact for scientific queries | *Rodolfo P. Rothlin, MD:* [safc@ama-med.org.ar](mailto:safc@ama-med.org.ar) |
| Public title | Telmisartan for Treatment of COVID-19 Patients |
| Scientific title | Telmisartan for Treatment of COVID-19 Patients: A Multi-center, Open, Randomized, Parallel-group study to Compare the Efficacy and Safety of 80 mg telmisartan [BID] in the treatment of hospitalized COVID-19 patients |
| Countries of recruitment | Argentina |
| Health condition(s) or problem(s) studied | COVID-19 |
| Intervention(s) | Active comparator:*Telmisartan 80 mg [BID]*  Placebo comparator: None. |
| Key inclusion and exclusion criteria | Ages eligible for study: ≥18 years Sexes eligible for study: both Accepts healthy volunteers: no Inclusion criteria:   * Age ≥18 years * Confirmed diagnosis of COVID-19 by PCR test. * Hospitalization for COVID-19 * Illness symptoms beginning 4 days or less prior to randomization.   Exclusion criteria:   * Admitted to ICU prior to randomization * Illness symptoms beginning more than 4 days prior to randomization. * Pregnancy. * Breast feeding. * Major hypersensibility to angiotensin receptor blockers (ARBs). * Systolic blood pressure < 100mmHg. * Serum potassium greater than 5.5 mEq/L. * AST and/or ALT > 3 times the upper limit of normal. * Serum creatinine higher than 3 mg/dL. * Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB. |
| Study type | Interventional Allocation: randomized Intervention model: parallel assignment Masking: None. Primary purpose: Treatment Phase IV |
| Date of first enrolment | 14 May 2020 |
| Target sample size | 400 participants |
| Recruitment status | Recruiting |
| Primary outcome(s) | Significative reduction in serum C reactive protein [Time Frame: Days 5 and 8] |
| Key secondary outcomes | Admission to intensive care unit (ICU) [Time Frame: Within 15 and 30 days after randomization]  Occurrence of mechanical ventilation [ Time Frame: Within 15 and 30 days after randomization]  Death [Time Frame: Within 15 days and 30 days]  Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first) [Time frame: Within 15 and 30 days after randomization]  Time from randomization to discharge (up to Day 15).  Proportion of hospitalized patients requiring supplemental oxygen at day 15.  Significative differences in serum lactate dehydrogenase [Time Frame: Days 5 and 8] |

1. Date and version identifier:

Issue Date: 12/7/2020

Protocol Amendment Number: 02

Authors: Rodolfo P. Rothlin, Mariano Duarte, Facundo Pelorosso, Liliana Nicolosi, Maria Victoria Salgado, Hector Vetuli.

Revision Chronology:

|  |  |
| --- | --- |
| March 2020 | Original version |
| July 2020 | Amendment No.01: Primary reason for amendment: Inclusion of a second site in study. |
| July 2020 | Amendment No.02: Primary reason for amendment:  Modification of primary endpoint: CRP measuring at day 15 was removed and day 5 was added |

1. Sources and types of financial, material, and other support:

The School of Medicine, University of Buenos Aires, will provide material support through permission to use Hospital de Clinicas facilities to carry out the trial. Also, all biochemical determinations at Hospital de Clinicas will be carried out at its Central Laboratory Facility (Director: Prof. Dra. Ángela Famiglietti).

Hospital Español de Buenos Aires will provide material support through permission to use its facilities to carry out the trial. Also, all biochemical determinations at this site will be carried out at the Central Laboratory Facility at Hospital Español.

Laboratorio Elea Phoenix will only provide the telmisartan tablets used for the study and will provide assistance in submitting the registration of this trial to www.ClinicalTrials.com.

Additional support will be provided by collaborator Dr. Carlos R. Rojo, MD.

1. Contributorship:
   1. Names, affiliations, and roles of protocol contributors:

Rodolfo P. Rothlin (RPR) conceived the study, postulated telmisartan as candidate agent as well as its dose and posology of administration.

RPR, Mariano Duarte (MD), Héctor Vetulli (HV), Facundo Pelorosso (FP) initiated the study design.

MD and Liliana Nicolosi lead recruitment and inpatient follow-up.

María Victoria Salgado (MVS) provides statistical expertise in clinical trial design and is conducting the primary statistical analysis.

Hector Vetuli (HV) contributed to original trial design.

All authors contributed to refinement of the study protocol and approved the final manuscript.

Author affiliations:

RPR: Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Buenos Aires, Argentina; Asociación Argentina de Medicamentos, Buenos Aires, Argentina.

MD: Hospital de Clínicas "José de San Martín", Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Segunda Cátedra de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.

FP: Servicio de Patología, Hospital de Alta Complejidad El Calafate SAMIC, Santa Cruz, Argentina; Asociación Argentina de Medicamentos, Buenos Aires, Argentina.

LN: Hospital Español de Buenos Aires, Buenos Aires, Argentina.

MVS: Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina; Servicio de Medicina Familiar, Hospital de Alta Complejidad El Calafate SAMIC, Santa Cruz, Argentina.

HV: Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos, Sanatorio Otamendi y Miroli, Buenos Aires, Argentina.

* 1. Trial Sponsor:

Primary sponsor: School of Medicine, University of Buenos Aires, Argentina.

Secondary sponsor: Laboratorio Elea Phoenix SA, Buenos Aires, Argentina.

* 1. Role of study sponsor and funders:

This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

The School of Medicine, University of Buenos Aires, will provide material support through permission to use Hospital de Clinicas facilities to carry out the trial. Also, all biochemical determinations at Hospital de Clinicas will be carried out at its Central Laboratory Facility (Director: Prof. Dra. Ángela Famiglietti).

Hospital Español de Buenos Aires will provide material support through permission to use its facilities to carry out the trial. Also, all biochemical determinations at this site will be carried out at the Central Laboratory Facility at Hospital Español.

Laboratorio Elea Phoenix will only provide the telmisartan tablets used for the study and will provide assistance in submitting the registration of this trial to www.ClinicalTrials.com.

1. Background and Rationale.
   1. Background and Rationale

* Background

COVID‐19, cause by the virus SARS‐CoV‐2, emerged as novel disease in Chine in late 2019 [1](#_ENREF_1),[2](#_ENREF_2).

Taking into account the characteristics of the mode of entry of this coronavirus to human cells through binding with Angiotensin Converting Enzyme 2 (ACE2) and extensive scientific and clinical evidence information on the Renin Angiotensin System, the hypothesis of the involvement of this system in the pathophysiology of COVID‐19 was born [3](#_ENREF_3).

The SARS-CoV-2 virus enters the airway and binds to the membrane protein ACE2 in type 2 alveolar cells via S (Spike) protein on its surface (after whose image the term coronavirus is coined). The S protein-ACE2 complex is internalized by endocytosis and facilitates the entry of each virion into the cytoplasm. For each intracellular entry, the function of one ACE2 molecule is lost, leading to a partial decrease or total loss of ACE2 enzymatic function in the alveolar cells of the lung [4](#_ENREF_4),[5](#_ENREF_5).

ACE2 produces the transformation of angiotensin II into angiotensin 1-7. Angiotensin II acts on AT1 receptors and causes vasoconstriction, apoptosis, proinflammatory effects, and fibrosis. In opposition, Angiotensin 1-7, acting on Mas receptors, causes vasodilation and anti-inflammatory effects. Partial decrease or total loss of ACE2 function in alveolar cells results in a deviation of the homeostatic balance of the Renin Angiotensin System in favor of the angiotensin II-AT1 receptor axis [6](#_ENREF_6),[7](#_ENREF_7). Indeed, it increases the tissue concentration of angiotensin II by decreasing its degradation and reduces the concentration of its physiological antagonist angiotensin 1-7 [8](#_ENREF_8).

The increased effects of angiotensin II on the lung interstitium can promote apoptosis, which, in turn, initiates an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade [9](#_ENREF_9). In certain patients this process reaches such clinical relevance that requires external oxygen supply and in severe cases an Acute Respiratory Distress Syndrome (ARDS) is installed (this correlates with an acute release -storm- of cytokines) [10](#_ENREF_10). Faced with the onset of the inflammatory process, a rapidly effective treatment is necessary to antagonize the cascading and self-sustaining phenomenon described.

Given that vaccines against COVID‐19 are still in development and an effective treatment against this new coronavirus is lacking, various pharmacological agents are being tested in clinical trials designed by institutions such as the WHO or scientific entities in different countries [11](#_ENREF_11). Among them, the use of angiotensin receptor blockers (ARB), such as losartan and telmisartan, as alternative options for treating COVID‐19 patients prior to development of ARDS has been recently proposed [3](#_ENREF_3). Prior use of angiotensin converting enzyme inhibitors (ACEi) or ARB was not significantly associated with COVID-19 diagnosis among patients with hypertension or with mortality or severe disease among patients diagnosed as having COVID-19 [12](#_ENREF_12), and a recent study found that inpatient treatment with ACEI/ARB was associated with lower risk of all‐cause mortality compared with ACEI/ARB nonusers [13](#_ENREF_13).

* Agent and dose selection.

ARBs are widely used to treat hypertension and there is an abundant clinical experience with its use; all representatives of this group are characterized by their excellent tolerance; furthermore, its adverse effects profile has been described as "placebo like” [14](#_ENREF_14),[15](#_ENREF_15).

The most suitable ARB to antagonize the proinflammatory effects of angiotensin II in a patient with a recent positive COVID-19 test should be the compound with the best pharmacological properties for this indication. From the comparative analysis of the available ARBs, telmisartan gathers properties that make it the best pharmacological tool to evaluate the hypothesis under discussion in a clinical trial.

Telmisartan, which is well absorbed after oral administration, is the ARB with the longest plasma half-life (24 h), it reaches the highest tissue concentrations due to its high lipid solubility and high volume of distribution (500 L), and dissociates more slowly after binding to the AT1 receptor, causing an apparently irreversible block [16](#_ENREF_16),[17](#_ENREF_17).

Clinical studies to evaluate the safety of telmisartan in healthy individuals or in hypertensive patients with daily doses of up to 160 mg, found no difference between those treated with telmisartan and the placebo group in frequency and intensity of adverse effects [14](#_ENREF_14),[15](#_ENREF_15),[18](#_ENREF_18).

Therefore, patients will be treated with telmisartan 80 mg BID during 14 days after enrolment. The choice of duration of treatment is given by the reported natural history of COVID-19 in hospitalized patients and in the proposed pathophysiological mechanism. Treatment duration will be 14 days; or until the occurrence of mechanical ventilation or any situation which precluded oral administration; or until hospital discharge or hospitalization for social or epidemiological reasons without requiring ongoing medical care.

* Choice of outcomes.

C reactive protein has been characterized as a bona fide marker of severity and prognosis of COVID-19 [19](#_ENREF_19). Significative reduction of C reactive protein levels at day 5 and 8 were chosen as primary endpoints.

Secondary outcomes are admission to intensive care unit (ICU) [Time Frame: Within 15 and 30 days after randomization], occurrence of mechanical ventilation [Time Frame: Within 15 and 30 days], death [ Time Frame: Within 15 and 30 days after randomization], composite occurrence of admission to ICU, mechanical ventilation or death (first occurrence) [Time frame: Within 15 and 30 days after randomization], proportion of patients requiring supplemental oxygen or with O2 saturation level lower than 96% while breathing room air at day 15, time from randomization to discharge (up to day 15), and significative differences in serum lactate dehydrogenase [Time Frame: Days 5 and 8]

* 1. Choice of comparators.

Control group will receive standard care. Although the use of placebo would be desirable, the urgency of COVID-19 pandemic precluded the acquisition of adequate placebo preparations.

1. Specific objectives and hypotheses.
   1. Research hypothesis

Telmisartan 80 mg BID significantly antagonizes the proinflammatory effect of Angiotensin II induced by reduction of cell membrane ACE2 presence by SARS-COV2 in hospitalized COVID-19 patients, leading to reduced plasma levels of C-reactive protein levels.

* 1. Study Objectives
* Primary Objective

The overall objective of the study is to evaluate the efficacy of telmisartan 80 mg BID relative to the control arm in reducing plasma levels of C-reactive protein in patients hospitalized with COVID-19 at days 5 and 8.

* Secondary Objectives

Evaluate clinical efficacy of telmisartan 80 mg BID as compared to the control arm as assessed by:

* + Proportion of patients requiring supplemental oxygen or with O2 saturation level lower than 96% while breathing room air at day 15.
  + Hospitalization: Time to discharge (up to Day 15).
  + Admission to ICU.
  + Occurrence of mechanical ventilation.
  + Mortality:

1. 15-day mortality
2. 30-day mortality

Evaluate the efficacy of telmisartan 80 mg BID relative to the control arm in reducing plasma levels of LDH in patients hospitalized with COVID-19 at day 5 and 8.

Evaluate the safety of the intervention through 14 days of follow-up as compared to the control arm as assessed by:

* Cumulative incidence of serious adverse events (SAEs)
* Cumulative incidence of Grade 3 and 4 adverse events (AEs).
* Discontinuation or temporary suspension of administration (for any reason).
* Changes in white cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, and AST over time.

1. Trial Design

“Telmisartan for Treatment of COVID-19 Patients” is a parallel group, randomized, two arm, open label, multicenter superiority trial with 1:1 allocation ratio with a primary endpoint of achieving significant reduction in plasma levels of C-reactive protein in COVID-19 patients at day 5 and 8 after randomization.

1. Study setting

The study will be conducted at two academic community Hospitals: Hospital de Clínicas “José de San Martín” (Facultad de Medicina, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina) and Hospital Español de Buenos Aires (Ciudad de Buenos Aires, Argentina).

1. Inclusion and exclusion criteria for participants

Patients (or a representative) must provide written, informed consent before any study procedures occur (see the Appendix for a sample of the Informed Consent Form).

Patients eligible for the trial must comply with all of the following at randomization:

Inclusion criteria:

* Age ≥18 years
* Confirmed diagnosis of COVID-19 by PCR test.
* Hospitalization for COVID-19
* Illness symptoms beginning 4 days or less prior to randomization.

Exclusion criteria:

* Admitted to ICU prior to randomization
* Illness symptoms beginning more than 4 days prior to randomization.
* Pregnancy.
* Breast feeding.
* Major hypersensibility to angiotensin receptor blockers (ARBs).
* Systolic blood pressure < 100mmHg.
* Serum potassium greater than 5.5 mEq/L.
* AST and/or ALT > 3 times the upper limit of normal.
* Serum creatinine higher than 3 mg/dL.
* Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB.

Admission to ICU prior to randomization was added as an exclusion criterion after initial enrolment. No patients were enrolled while being in ICU. Also, initial patient enrolment showed a short time between onset of symptoms and randomization at site 1 (Hospital de Clínicas). Therefore, to reduce intersite variability, a new exclusion criterion was added, precluding future participation of patients with onset of symptoms longer than 4 days prior to randomization.

1. Interventions
   1. Interventions for each group

Eligible participants will be randomized in equal proportions between telmisartan 80 mg bid and standard care, receiving either a twice daily, tablets, 80 mg telmisartan for 14 days, or standard care.

The study drug will be provided by Laboratorio Elea Phoenix (Buenos Aires, Argentina) in its commercially available form BERTEL.

* 1. Modifications:

Administration of telmisartan will continue for 14 days after randomization or until discharge or until the occurrence of mechanical ventilation or any situation which precluded oral administration of telmisartan.

Telmisartan administration will be stopped if the participant was admitted for plasma administration from convalescent patients.

Participants missing more than two doses of telmisartan will be excluded from further analysis.

Participants developing systolic blood pressure < 90mmHg but > 80 mmHg will skip one telmisartan dose and reevaluated after 12h. If a second reading was made at that time of systolic blood pressure < 90mmHg the participant will stop receiving telmisartan altogether and will be excluded from further analysis.

Participants developing systolic blood pressure < or equal to 80mmHg at any time will stop receiving telmisartan altogether and will be excluded from further analysis.

During the initial phase of this study, the use of plasma from recovered COVID-19 patients became more frequent. Recently, it has been described that the increase of antibodies against SARS-CoV-2 Spike protein (S-IgG) positively correlates with the decrease of CRP in non-ICU patients [20](#_ENREF_20). Therefore, to avoid a possible confounder, patients receiving plasma from COVID-19 recovered patients will be censored at the day of their last observed assessment before plasma administration.

* 1. Adherence:

Each dose of telmisartan will be administered by a member of the clinical research team or designated professional that is qualified and licensed to administer the drug.

* 1. Concomitant Care:

Concomitant care will include but not be limited to any standard established by Argentina’s National Health Ministry during the COVID-19 pandemic (<http://www.msal.gob.ar>).

A select concomitant medications will be captured in this trial. The list of medications will be assessed from 4 days prior to enrollment to Day 15.

Participants enrolled for investigational treatment with plasma from convalescent COVID patients will stop further treatment and analysis in this trial.

1. Outcomes
2. Primary outcomes

Significative reduction in serum C reactive protein [Time Frame: Days 5 an 8]

C-reactive protein will be measured at days 1, 5 and 8 after randomization. The serum levels of CRP can effectively assess disease severity and predict outcome in patients with COVID-19 [19](#_ENREF_19).

1. Secondary outcomes

Admission to intensive care unit (ICU) [Time Frame: Within 15 and 30 days from randomization]

Occurrence of mechanical ventilation [ Time Frame: Within 15 and 30 days from randomization]

Death [ Time Frame: Within 15 days, 30, and 90 days from randomization]

Composite occurrence of admission to ICU, mechanical ventilation or death [Time frame: Within 15 and 30 days after enrollment]

Proportion of patients requiring supplemental oxygen or with O2 saturation level lower than 96% while breathing room air at day 15.

Time from randomization to discharge (up to Day 15).

Significative differences in plasma levels of lactate dehydrogenase [Time Frame: Days 5 and 8]

13. Participant timeline: according to the following scheme:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Activity/Day**  **(+/- Window)** | **Screen for eligibility**  **(day -1 or 1)** | **Baseline**  **(day 1)** | **Daily until hospital discharge** | **Day 5**  **(5 ± 2)** | **Day 8**  **(8 ± 2)** | **Day 15**  **(15 ± 2)** | **Day 30**  **(30 ± 2)** |
| **Eligibility** |  |  |  |  |  |  |  |
| Informed consent | X |  |  |  |  |  |  |
| Demographics and medical history | X |  |  |  |  |  |  |
| Review SARS-CoV-2 results | X |  |  |  |  |  |  |
| **Study intervention** |  |  |  |  |  |  |  |
| Randomization |  | X |  |  |  |  |  |
| Administration of telmisartan |  | | Twice daily telmisartan 80 mg until day 14 or discharge |  |  |  |  |
| Vital signs including SpO2 |  |  | X |  |  |  |  |
| Clinical data collection |  |  |  | X | X | X | X |
| Adverse event evaluation |  |  | X |  |  |  |  |
| **Safety laboratory** |  |  |  |  |  |  |  |
| Safety hematology, chemistry and  liver tests |  | X |  | X | X |  |  |
| **Research laboratory** |  |  |  |  |  |  |  |
| C reactive protein |  | X |  | X | X |  |  |
| LDH |  | X |  | X | X |  |  |

14. Sample size

For sample size calculations, we used our main outcome level as reference (CRP), and used a repeated measures model. Calculations were done using the GLIMMPSE (General Linear Mixed Model Power and Sample Size) software[21](#_ENREF_21), freely available at <https://glimmpse.samplesizeshop.org/>.

Changes in sample size calculation were made according to changes made in primary outcome.

We determined a 0.80 power and a type I error rate of 0.05, and chose the Hotelling Lawley Trace test. We assumed an initial CRP level of 60 mg/L in both groups, with an elevation on day 5 in the control group (up to 72 mg/L, a 20% more) and a descend in the telmisartan group to 36 mg/L (40% less). We then assumed that the mean decreased at day 8 in both groups. Accounting for variability on these assumptions, we used a scale factor of 0.5 for the mean and 2 for the standard deviation.

The following table specifies the inputs used:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Inputs used for sample size calculation | | | | | |
| Hypothesis tested | Time x treatment | | | | |
| Power | 0.8 | | | | |
| Type I error rate | 0.05 | | | | |
| Group size ratio | 1:1 | | | | |
| CRP mean values (mg/L) | Control | T0=60 | T1 (5 days) =72 | T2 (8 days) = 45 | Scale factor: 0.5 |
| Telmisartan | T0=60 | T1 (5 days) =36 | T2 (8 days) = 20 |
| CRP Standard deviation (mg/L) | Initial=33 | 1 | 0.7 (decay) | 0.2 (decay) | Scale factor: 2 |

We obtained a total population sample of 390 participants (195 in each group), which we roughly approximated to 400 (200 in each group).

15. Recruitment

It is anticipated that patients with COVID-19 will present to participating hospitals, and that no external recruitment efforts towards potential subjects are needed.

Recruitment efforts may also include dissemination of information about this trial to other medical professionals / hospitals.

Patients that are confirmed to have SARS-CoV-2 will be assessed for eligibility. Information about the study will be presented to potential subjects (or legally authorized representative), and questions will be asked to determine potential eligibility.

16. Sequence generation

Method of sequence generation: Randomization sequence was obtained by using QuickCalcs (Graphad Software).

Allocation ratio: 1:1

Type of randomization: simple

17. Blinding

No blinding was incorporated in the design of this trial.

18. Data collection methods

1. Plans for assessment and collection of outcome, baseline, and other trial data:

After obtaining informed consent from confirmed positive SARS-CoV-2 patients, some or all of the following assessments will be performed to determine eligibility requirements, as specified in the inclusion and exclusion criteria: obtain a detailed medical history, including day of onset of COVID-19 symptoms, medication allergies, and review medications and therapies for this current illness; counsel women to use adequate birth control methods required during the trial to avoid pregnancy; obtain weight; vital signs including SpO2; obtain blood for safety laboratory evaluations. The overall eligibility of the subject to participate in the study will be assessed once all screening values are available. The screening process can be suspended prior to complete assessment at any time if exclusions are identified by the study team. Study subjects who qualify will be immediately randomized.

Although all previous medical history will be collected, focus will be put on determining the presence of the following conditions: COPD, Asthma, Hypertension, Diabetes, Dyslipidemia, obesity, previous stroke, active cancer, immunosuppression, chronic kidney disease, chronic liver disease, heart failure, hypothyroidism.

Other laboratory measurements recorded at baseline: Serum albumin, ESR, Urea, glucose, Glycosylated hemoglobin.

Vital sign will be measured at least once a day.

Every day while the patient is hospitalized, we will assess: assessed: oxygen requirement, non-invasive mechanical ventilation, admission to ICU, mechanical ventilator requirement (via endotracheal tube or tracheostomy tube), mortality, convalescent plasma administration.

At days 1, 5 and 8 blood will be drawn to obtain determination of safety measures (liver enzymes, creatinine, hematological indices) and to obtain C-reactive protein and LDH plasma levels.

1. Retention

Retention of subjects in this trial is very important for determining the secondary endpoint. As such, after hospital discharge, participating follow-up visits will be conducted by phone to obtain information about mortality.

19. Data management

All data will be entered electronically in pre-arranged password protected forms. Original study forms will be entered and kept safe on file at the participating sites.

20. Statistical methods

This is a two arm, open label, randomized trial testing a superiority hypothesis with a two-sided type I error rate of 0.05.

Descriptive analysis will be conducted according to the appropriate summary statistics (e.g., proportions for categorical data, means with 95% confidence intervals for continuous data, median for time-to-event data).

Comparison of C-reactive protein and LDH levels at day 1, 5 and 8 will be analyzed by means of a mixed-effects model analysis for repeated measures followed by a Šídák multiple comparison test. This mixed model uses a compound symmetry covariance matrix, and is fit using Restricted Maximum Likelihood (REML). In the absence of missing values, this method gives the same p values and multiple comparisons tests as repeated measures ANOVA. In the presence of missing values (missing completely at random), the results can be interpreted like repeated measures ANOVA. The Geisser-Greenhouse correction will be used.

Analysis of time to discharge between days 1 and 15 will be done calculating proportions using the Kaplan-Meier method, standard errors were calculated by the method of Greenwood, and the resulting curves will be compared by a log-rank test. All deaths within that period will be considered censored at day 15 (the worst possible rank). Participants receiving plasma from convalescent COVID-19 patients will be censored at the day of plasma administration. Patients admitted to ICU will be included in this analysis until time to discharge. Patients that are still hospitalized at day 15 will be censored at that day.

Difference in proportions (ICU, mechanical ventilation, death, need for oxygen supplementation at day 15) will be compared by Chi-square test.

1. Sequential monitoring and early stopping.

Outcomes will be monitored throughout the trial and used for interim analyses of efficacy and safety.

A first interim analysis will be conducted on July 31st 2020; due to the lack of vaccine and effective treatments at the time of writing of this protocol and the urgent public health situation, we have planned this first analysis not based on the number of patients enrolled but at 2 and a half months from initial recruitment.

A second interim analysis is planned to be conducted when a total of 140 patients are recruited. Although our estimated sample size was 390, it is worth noticing that this number accounts for a scale factor on both the mean and the variability estimations; without these factors, the estimated sample size was 52 patients total, and with only a variability factor of 2 the total estimated number was 100. Therefore, we evaluate that, if our original mean and variability assessments are correct or only slightly deviated, efficacy can be conservative appraised with 140 patients in total.

A third interim analysis will be conducted when 200 patients total are recruited (half of our estimated sample size).

Early stopping due to efficacy is defined as achieving significant differences between groups in our main outcome. To control across repeated analyses for Type I error, set at 0.05, critical values for interim testing will be defined based on O'Brien-Fleming’s boundaries. With this approach, interim tests early in the trial are conservative and the reduction in the overall power of the trial caused by interim testing is small. These boundaries will not be used for safety outcomes.

21. Monitoring of adverse effects

Adverse effects mean any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related. An adverse effect can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product. Any medical condition that is present at the time that the subject is screened will be considered as preexistent and not reported as an adverse effect. However, if the severity of any pre-existing medical condition increases, it should be recorded as an adverse effect.

An adverse effect or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in any of the following outcomes: Death (grade 4), a life-threatening adverse effect (grade 4), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions (grade 3).

For each reported adverse reaction, the investigator must assess the relationship of the event to the study product using the following guideline:

* Related (the adverse effect is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the adverse effect, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the adverse effect.
* Not Related (there is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established)

Given the nature of severity of the underlying illness, subjects will have many symptoms and abnormalities in vitals and laboratory. All Grade 3 and 4 adverse effects will be captured as adverse effects in this trial.

21. Research ethics approval

This protocol and the template informed consent form contained in the Appendix has been evaluated and approved by the Ethics Committee of the Hospital de Clinicas “Jose de San Martin”, and by de Institutional Review Board of the Hospital Español de Buenos Aires.

22. Protocol Amendments

Any modifications to the protocol which may impact on the conduct of the study, potential benefit of the participant or may affect participant safety, including changes of study objectives, study design, participant population, sample sizes, study procedures, or significant administrative aspects will require a formal amendment to the protocol. Such an amendment will be approved by the sites ethics committees prior to implementation.

23. Consent

Investigators will obtain a subject’s informed consent before any study procedures or data collection are performed. Typically, subjects or their legally authorized representatives receive a concise and focused presentation of key information about the clinical trial, both verbally and with a written consent form. Subjects will be asked to read and review the consent form. Subjects or their legally authorized representatives must sign the informed consent form prior to starting any study procedures.

24. Confidentiality

All study-related information will be stored securely at the study site. All participant information will be stored in locked file cabinets in areas with limited access. All laboratory specimens, reports, data collection, process, and administrative forms will be identified by a coded ID [identification] number only to maintain participant confidentiality. All records that contain names or other personal identifiers, such as locator forms and informed consent forms, will be stored separately from study records identified by code number. All local databases will be secured with password-protected access systems. Forms, lists, logbooks, appointment books, and any other listings that link participant ID numbers to other identifying information will be stored in a separate, locked file in an area with limited access.

25. Declaration of Interests

The authors state no conflict of interests at the writing of this protocol.

26. Access to data

All Principal Investigators will be given access to the cleaned data sets. Principal Investigators will have direct access to their own site’s data sets, and will have access to other sites data by request. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information.

27. Trial results

Following completion of the study, the results of this research will be submitted for publication in a scientific journal. Data will be available immediately following publication, with no end date.

**APPENDIX: CONSENT FORM (SPANISH)**

**CONSENTIMIENTO INFORMADO**

**Telmisartán como Tratamiento de Pacientes con COVID 19: Estudio Randomizado Controlado Abierto**

Patrocinador: **Facultad de Medicina Universidad de Buenos Aires**

Lugar de Realización: **Hospital de Clínicas José de San Martín/Hospital Español de Buenos Aires**

Investigador Principal:

Investigador Responsable:

ID Paciente ………………………….

Ciudad de Buenos Aires ………… de ……………….. de 2020

Yo ………………………………...……….. con DNI ………….. LC / CI………………………

* Estoy siendo invitado a participar voluntariamente del Trabajo de Investigación que se está llevando a cabo en el Hospital de Clínicas José de San Martín/Hospital Español patrocinado por la Facultad de Medicina de la Universidad de Buenos Aires. En él se está estudiando un tratamiento para la Infección por COVID 19, y donde luego de evaluarse el riesgo médico potencial que conlleva esta afección y la intervención en estudio, se cuenta con suficientes elementos científicos sólidos que justifiquen la intervención propuesta. El Principal objetivo del presente estudio clínico es evaluar si el fármaco Telmisartán, que se utiliza para el tratamiento de la Hipertensión Arterial, produce un efecto farmacológico antagónico del desarrollo de los fenómenos patológicos sistémicos inducidos por la infección de COVID 19 o Coronavirus.
* Se me ha explicado que este estudio es gratuito y que, en caso de acceder a participa en forma voluntaria, la asignación será por azar y puede corresponderme el medicamento en estudio o el grupo control (no reciben el medicamento). También se me realizarán revisiones clínicas diarias y exámenes complementarios de laboratorio.
* Mientras curse este proceso permaneceré internado hasta su resolución y el egreso tendrá lugar con pautas de alarma escritas cuando correspondiese. En ese caso se me solicitará un teléfono donde pueda ser llamado para nuevos controles o para tener conocimiento de mi estado de salud, al tiempo que se me brindará uno para llamar ante cualquier eventualidad. También me fue explicado que diariamente podré saber acerca de mi evolución y que esta información, tanto como la mía personal, serán guardadas acorde a las normas de buena práctica y de confidencialidad de los datos, pudiendo en este marco comunicarse en reuniones o en publicaciones científicas.
* Habiendo comprendido lo expresado anteriormente, este consentimiento es dado libremente y por mi voluntad, en pleno uso de mis facultades mentales y siendo legalmente apto para ello. Queda también establecido que es mi derecho, en cualquier momento del estudio, retirarme del mismo sin que ello produzca un perjuicio para mí, o afecte la relación médico – paciente.

Firma del Paciente ………………………………………………………………………………………………

Aclaración ………………………………………………………………………………………………

Firma de Médico ………………………………………………………………………………………………

Aclaración ………………………………………………………………………………………………

Firma del Testigo ………………………………………………………………………………………………

Aclaración ………………………………………………………………………………………………

**REFERENCES**

1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. 2020;92:418-23.

2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. J Med Virol 2020;382:1199-207.

3. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug development research 2020.

4. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.

5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020;94.

6. Paz Ocaranza M, Riquelme JA, García L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. 2020;17:116-29.

7. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Nat Rev Cardiol 2011;20:62-8.

8. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life sciences 2020;63:364-74.

9. Cardoso VG, Gonçalves GL, Costa-Pessoa JM, et al. Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC-δ/p38 MAPK pathway activation and trough increased Na(+)/H(+) exchanger isoform 1 activity. BMC Nephrol 2018;19:179.

10. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.

11. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020;83:534-6.

12. Fosbøl EL, Butt JH, Østergaard L, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA 2020;324:168-77.

13. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020;126:1671-81.

14. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008;1:32-40.

15. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.

16. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6.

17. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013;65:809-48.

18. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67.

19. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020;127:104370.

20. Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging microbes & infections 2020;9:940-8.

21. Kreidler SM, Muller KE, Grunwald GK, et al. GLIMMPSE: Online Power Computation for Linear Models with and without a Baseline Covariate. Journal of statistical software 2013;54.